Here, six house and techno artists provide a look into what it’s like being a tastemaker spinning at Time Warp. They discuss their favorite memories, why the event is special to them and more.

Lilly Endowment Inc. is supporting the renewal of Indiana K-12 educators through its 2025 Teacher Creativity Fellowship ...

Google Deepmind co-founder Demis Hassabis talks to FT editor Roula Khalaf about the real world healthcare applications of AI and how his ground-breaking work on the structure of proteins could acceler ...

With their win in last year's Super Bowl, Patrick Mahomes and the Kansas City Chiefs officially became the NFL's latest dynasty. On Sunday, the Chiefs can make more history while adding to their ...

Eli Lilly, which first broke ground on its state-of-the-art Concord manufacturing facility ... professor of politics and history at Catawba College, who spoke to the crowd about the 2024 elections.

“Oklahoma City, for instance, has leveraged its history of leadership in the energy industry to ... and as a Senior Sales Representative with Eli Lilly & Company. As Director, she has primary ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...

During the last three months, 7 analysts shared their evaluations of Eli Lilly LLY, revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings, showcasing ...